BTIG Slashes Ginkgo Bioworks Target to $5 on Lab Shift

BTIG lowered its price target on Ginkgo Bioworks Holdings Inc to $5.00 from $9.00 while maintaining a Sell rating, pointing to a lack of visibility as the biotechnology firm restructures its operations around Autonomous Labs.

"We look for greater visibility into its progress to build out and monetize Autonomous Labs, and as a result, we reiterate our Sell rating on Ginkgo, and lower our PT from $9 to $5," BTIG analysts said in a note.

Second-Quarter Revenue Decline and Guidance Suspension

The analyst downgrade follows Ginkgo Bioworks' second-quarter 2026 earnings report, which revealed revenue of $20 million. That figure missed the consensus forecast of $29.9 million and represented a 48% decline compared to the same period in the previous year.

During the operational restructuring, Ginkgo also decided to suspend its forward revenue guidance, leaving investors with fewer visibility metrics to gauge near-term financial performance during the transition period.

Transition to Autonomous Labs

The strategic shift involves several structural changes across the company's asset base. Ginkgo recently announced the divestiture of its Biosecurity segment alongside plans to decommission most of its traditional lab benches to construct a large, centralized autonomous laboratory.

As part of this automation push, the company plans to increase its RAC cart automation systems, originally acquired through the buyout of Zymergen in 2022, within its Boston facility from 50 to 100 operating systems by year-end 2026.

What Is at Stake for Shareholders

The pivot toward automation represents an overhaul of Ginkgo's core foundry model. By dismantling conventional lab infrastructure in favor of automated systems, the company aims to reduce long-term operational costs and improve throughput for synthetic biology engineering, though execution risks remain central to analysts' cautious stances.